메뉴 건너뛰기




Volumn 2016, Issue 11, 2016, Pages

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; BETA1A INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA SERINE;

EID: 85000580279     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009333.pub3     Document Type: Review
Times cited : (19)

References (122)
  • 1
    • 70449360324 scopus 로고    scopus 로고
    • New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate
    • [4457749]
    • Cadavid D, Cheriyan J, SkurnickJ, LincolnJ A, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Journal Neurology Neurosurgery and Psychiatry 2009;80(12):1337-43. [4457749]
    • (2009) Journal Neurology Neurosurgery and Psychiatry , vol.80 , Issue.12 , pp. 1337-1343
    • Cadavid, D.1    Cheriyan, J.2    Skurnick, J.3    LincolnJ, A.4    Wolansky, L.J.5    Cook, S.D.6
  • 2
  • 3
    • 67649476210 scopus 로고    scopus 로고
    • Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study
    • [4457751]
    • Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72(23):1976-83. [4457751]
    • (2009) Neurology , vol.72 , Issue.23 , pp. 1976-1983
    • Cadavid, D.1    Wolansky, L.J.2    Skurnick, J.3    Lincoln, J.4    Cheriyan, J.5    Szczepanowski, K.6
  • 5
    • 80054944461 scopus 로고    scopus 로고
    • Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    • [3193451]
    • Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 2012;18(4):418-24. [3193451]
    • (2012) Multiple Sclerosis Journal , vol.18 , Issue.4 , pp. 418-424
    • Calabrese, M.1    Bernardi, V.2    Atzori, M.3    Mattisi, I.4    Favaretto, A.5    Rinaldi, F.6
  • 6
    • 84857714278 scopus 로고    scopus 로고
    • The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics
    • [4457754]
    • Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Multiple Sclerosis and Related Disorders 2012;1(2):81-6. [4457754]
    • (2012) Multiple Sclerosis and Related Disorders , vol.1 , Issue.2 , pp. 81-86
    • Lindsey, J.W.1    Scott, T.F.2    Lynch, S.G.3    Cofield, S.S.4    Nelson, F.5    Conwit, R.6
  • 7
    • 84873112669 scopus 로고    scopus 로고
    • The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - clinical outcomes
    • [4457755]
    • Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, Nelson F, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - clinical outcomes. Neurology 2012;78(1 Suppl 1):PL02.003. [4457755]
    • (2012) Neurology , vol.78 , Issue.1
    • Lublin, F.1    Cofield, S.2    Cutter, G.3    Conwit, R.4    Narayana, P.5    Nelson, F.6
  • 8
    • 84896717226 scopus 로고    scopus 로고
    • EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement
    • [4457756]
    • Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Neurology 2013;80(7 Suppl 1):P04.121. [4457756]
    • (2013) Neurology , vol.80 , Issue.7 , pp. P04121
    • Lublin, F.1    Cofield, S.2    Cutter, G.3    Salter, A.4    Wang, J.5    Conwit, R.6
  • 9
    • 84896715772 scopus 로고    scopus 로고
    • Relapse activity in the CombiRx trial: blinded, 7-year extension results
    • [4457757]
    • Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. Relapse activity in the CombiRx trial: blinded, 7-year extension results. Neurology 2013;80(7 Suppl 1):S01.002. [4457757]
    • (2013) Neurology , vol.80 , Issue.7 , pp. S01002
    • Lublin, F.1    Cofield, S.2    Cutter, G.3    Salter, A.4    Wang, J.5    Conwit, R.6
  • 10
  • 11
    • 85032039060 scopus 로고    scopus 로고
    • The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - MRI outcomes
    • [4457759]
    • Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - MRI outcomes. Neurology 2012;78(Suppl 1):S11.002. [4457759]
    • (2012) Neurology , vol.78 , pp. S11002
    • Wolinsky, J.1    Narayana, P.2    Nelson, F.3    Datta, S.4    Cofield, S.5    Cutter, G.6
  • 12
    • 84896725660 scopus 로고    scopus 로고
    • MRI outcomes in CombiRx: blinded, 7-year extension results
    • [4457760]
    • Wolinsky J, Salter A, Narayana P, Datta S, Nelson F, Cofield S, et al. MRI outcomes in CombiRx: blinded, 7-year extension results. Neurology 2013;80(Suppl 7):S01.003. [4457760]
    • (2013) Neurology , vol.80 , pp. S01003
    • Wolinsky, J.1    Salter, A.2    Narayana, P.3    Datta, S.4    Nelson, F.5    Cofield, S.6
  • 14
    • 51449101000 scopus 로고    scopus 로고
    • Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
    • [3193461]
    • Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology 2008;7(10):903-14. [3193461]
    • (2008) Lancet Neurology , vol.7 , Issue.10 , pp. 903-914
    • Mikol, D.D.1    Barkhof, F.2    Chang, P.3    Coyle, P.K.4    Jeffery, D.R.5    Schwid, S.R.6
  • 15
    • 51449088420 scopus 로고    scopus 로고
    • REGARD: what can we learn from randomised, open-label, head-to-head studies?
    • [4457762]
    • Sørensen S. REGARD: what can we learn from randomised, open-label, head-to-head studies?. Lancet 2008;7(10):864-6. [4457762]
    • (2008) Lancet , vol.7 , Issue.10 , pp. 864-866
    • Sørensen, S.1
  • 16
    • 84925857753 scopus 로고    scopus 로고
    • Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
    • [A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis]. (first received 26 January 2010). [4457763]
    • NCT01058005 Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis [A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis]. clinicaltrials.gov/show/NCT01058005 (first received 26 January 2010). [4457763]
  • 17
    • 79954574768 scopus 로고    scopus 로고
    • Interferon-1b and glatiramer acetate effects on permanent black hole evolution
    • [4457765]
    • Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, et al. Interferon-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76(14):1222-8. [4457765]
    • (2011) Neurology , vol.76 , Issue.14 , pp. 1222-1228
    • Filippi, M.1    Rocca, M.A.2    Camesasca, F.3    Cook, S.4    O'Connor, P.5    Arnason, B.G.6
  • 18
    • 84856734786 scopus 로고    scopus 로고
    • Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the beyond trial
    • [4457766]
    • Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the beyond trial. Multiple Sclerosis 2012;18(2):181-95. [4457766]
    • (2012) Multiple Sclerosis , vol.18 , Issue.2 , pp. 181-195
    • Goodin, D.S.1    Hartung, H.P.2    O'Connor, P.3    Filippi, M.4    Arnason, B.5    Comi, G.6
  • 19
    • 84880265360 scopus 로고    scopus 로고
    • Efficacy and safety of interferon beta-1b SC in older RRMS patients-a post hoc analysis of the BEYOND study
    • [4457767]
    • Lampl C, Nagl S, Arnason B, Comi G, O' Connor P, Cook S, et al. Efficacy and safety of interferon beta-1b SC in older RRMS patients-a post hoc analysis of the BEYOND study. Journal of Neurology 2013;260(7):1838-45. [4457767]
    • (2013) Journal of Neurology , vol.260 , Issue.7 , pp. 1838-1845
    • Lampl, C.1    Nagl, S.2    Arnason, B.3    Comi, G.4    O' Connor, P.5    Cook, S.6
  • 20
    • 69949098534 scopus 로고    scopus 로고
    • 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    • [4457772]
    • O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology 2009;8(10):889-97. [4457772]
    • (2009) Lancet Neurology , vol.8 , Issue.10 , pp. 889-897
    • O'Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Goodin, D.6
  • 21
    • 51449084771 scopus 로고    scopus 로고
    • Interferon beta-1b 500 mcg, Interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the betaferon® efficacy yielding outcomes of a new dose study
    • [4457768]
    • O' Connor P, Arnason B, Comi GC, Filippi M, Cook S, Newark NJ, et al. Interferon beta-1b 500 mcg, Interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the betaferon® efficacy yielding outcomes of a new dose study. Neurology 2008;71:LBS.004. [4457768]
    • (2008) Neurology , vol.71
    • O' Connor, P.1    Arnason, B.2    Comi, G.C.3    Filippi, M.4    Cook, S.5    Newark, N.J.6
  • 22
    • 85000741361 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata
    • [4457771]
    • O' Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2011; Vol. 10, issue 2:115. [4457771]
    • (2011) Lancet Neurology , vol.10 , Issue.2 , pp. 115
    • O' Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Goodin, D.6
  • 23
    • 69949098534 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    • Errata].[4457769]
    • O' Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study [Errata]. Lancet Neurology 2009;8(11):981. [4457769]
    • (2009) Lancet Neurology , vol.8 , Issue.11 , pp. 981
    • O' Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Goodin, D.6
  • 24
    • 85000549116 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata
    • [4457770]
    • O' Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2012;11(1):27. [4457770]
    • (2012) Lancet Neurology , vol.11 , Issue.1 , pp. 27
    • O' Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Goodin, D.6
  • 26
    • 85000675690 scopus 로고    scopus 로고
    • Randomized, open-label study to evaluate patient-reported outcomes (PRO) with fingolimod after changing from prior disease-modifying therapy (DMT) for relapsing multiple sclerosis
    • September 25 - 27, 2011; San Diego, California.. [3193474]
    • Barbato LM, Schofield L, McCague K, Pestreich L, Tobias K, Malhotra M, et al. Randomized, open-label study to evaluate patient-reported outcomes (PRO) with fingolimod after changing from prior disease-modifying therapy (DMT) for relapsing multiple sclerosis. American Neurological Association (ANA) 136th Annual Meeting, September 25 - 27, 2011; San Diego, California. 2011. [3193474]
    • (2011) American Neurological Association (ANA) 136th Annual Meeting
    • Barbato, L.M.1    Schofield, L.2    McCague, K.3    Pestreich, L.4    Tobias, K.5    Malhotra, M.6
  • 27
    • 85000556260 scopus 로고    scopus 로고
    • The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
    • [3193476]
    • Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. Bacteriologia, Virusologia, Parazitologia, Epidemiologia 2011;11(144):2-7. [3193476]
    • (2011) Bacteriologia, Virusologia, Parazitologia, Epidemiologia , vol.11 , Issue.144 , pp. 2-7
    • Beer, K.1    Müller, M.2    Hew-Winzeler, A.M.3    Bont, A.4    Maire, P.5    You, X.6
  • 28
    • 41049110806 scopus 로고    scopus 로고
    • Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina
    • [3193478]
    • Carra A, Onaha P, Luetic G, Burgos M, Crespo E, Deri N, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. European Journal Neurology 2008;15(4):386-93. [3193478]
    • (2008) European Journal Neurology , vol.15 , Issue.4 , pp. 386-393
    • Carra, A.1    Onaha, P.2    Luetic, G.3    Burgos, M.4    Crespo, E.5    Deri, N.6
  • 29
    • 77955442859 scopus 로고    scopus 로고
    • Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis
    • [3193480]
    • Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010;70(12):1545-77. [3193480]
    • (2010) Drugs , vol.70 , Issue.12 , pp. 1545-1577
    • Carter, N.J.1    Keating, G.M.2
  • 30
    • 70350786389 scopus 로고    scopus 로고
    • Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
    • [3193482]
    • Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11. [3193482]
    • (2009) Lancet , vol.374 , pp. 1503-1511
    • Comi, G.1    Martinelli, V.2    Rodegher, M.3    Moiola, L.4    Bajenaru, O.5    Carra, A.6
  • 31
    • 79551484331 scopus 로고    scopus 로고
    • Phase III dose-comparison study of glatiramer acetate for multiple sclerosis
    • [3193484]
    • Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology 2011;69(1):75-82. [3193484]
    • (2011) Annals of Neurology , vol.69 , Issue.1 , pp. 75-82
    • Comi, G.1    Cohen, J.A.2    Arnold, D.L.3    Wynn, D.4    Filippi, M.5
  • 32
    • 84860273268 scopus 로고    scopus 로고
    • Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis
    • [3193486]
    • Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. European of Journal Clinical Pharmacology 2011;68(4):441-8. [3193486]
    • (2011) European of Journal Clinical Pharmacology , vol.68 , Issue.4 , pp. 441-448
    • Del Santo, F.1    Maratea, D.2    Fadda, V.3    Trippoli, S.4    Messori, A.5
  • 33
    • 22144446357 scopus 로고    scopus 로고
    • Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study
    • [3193488]
    • Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis 2005;11(4):420-4. [3193488]
    • (2005) Multiple Sclerosis , vol.11 , Issue.4 , pp. 420-424
    • Ghezzi, A.1    Amato, M.P.2    Capobianco, M.3    Gallo, P.4    Marrosu, G.5    Martinelli, V.6
  • 35
    • 0035211356 scopus 로고    scopus 로고
    • A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy
    • [3193490]
    • Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Multiple Sclerosis (Houndmills, Basingstoke, England) 2001;7(6):349-53. [3193490]
    • (2001) Multiple Sclerosis (Houndmills, Basingstoke, England) , vol.7 , Issue.6 , pp. 349-353
    • Khan, O.A.1    Tselis, A.C.2    Kamholz, J.A.3    Garbern, J.Y.4    Lewis, R.A.5    Lisak, R.P.6
  • 36
    • 84155164255 scopus 로고    scopus 로고
    • Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study
    • [3193492]
    • Khan O, Bao F, Shah M, Caon C, Alexandros T, Selis A, et al. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. Journal of the Neurological Sciences 2012;312:7-12. [3193492]
    • (2012) Journal of the Neurological Sciences , vol.312 , pp. 7-12
    • Khan, O.1    Bao, F.2    Shah, M.3    Caon, C.4    Alexandros, T.5    Selis, A.6
  • 37
    • 84881226959 scopus 로고    scopus 로고
    • Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
    • [3193494]
    • Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals of Neurology 2013;73(6):705-13. [3193494]
    • (2013) Annals of Neurology , vol.73 , Issue.6 , pp. 705-713
    • Khan, O.1    Rieckmann, P.2    Boyko, A.3    Selmaj, K.4    Zivadinov, R.5
  • 38
    • 77957083422 scopus 로고    scopus 로고
    • A randomised controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis
    • [3193496]
    • Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, et al. A randomised controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Archives of Neurology 2010;67(9):1055-61. [3193496]
    • (2010) Archives of Neurology , vol.67 , Issue.9 , pp. 1055-1061
    • Khoury, S.J.1    Healy, B.C.2    Kivisäkk, P.3    Viglietta, V.4    Egorova, S.5    Guttmann, C.R.6
  • 39
    • 76349097974 scopus 로고    scopus 로고
    • Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies
    • [Traitements de fond de la sclérose en plaques: enseignements des études randomisées comparatives directes]. [3193500]
    • Ouallet JC. Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies [Traitements de fond de la sclérose en plaques: enseignements des études randomisées comparatives directes]. Reveu Neurologique 2010;166(1):21-31. [3193500]
    • (2010) Reveu Neurologique , vol.166 , Issue.1 , pp. 21-31
    • Ouallet, J.C.1
  • 40
    • 84856163998 scopus 로고    scopus 로고
    • Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome
    • [3193502]
    • Qizilbash N, Mendez I, Sanchez-de la Rosa R. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome. Multiple Sclerosis Clinical Therapy 2012;34(1):159-76. [3193502]
    • (2012) Multiple Sclerosis Clinical Therapy , vol.34 , Issue.1 , pp. 159-176
    • Qizilbash, N.1    Mendez, I.2    Sanchez-de la Rosa, R.3
  • 41
    • 85000433638 scopus 로고    scopus 로고
    • Twelve-month comparative study of the impacts of IFNb-1a (Avonex), IFNb-1b (Betaseron) and glatiramer acetate (Copaxone) on the clinical, MRI and immunological responses in relapsing-remitting multiple sclerosis
    • [3193504]
    • Salama HH, Abu-Hashim EM, El Bakry MA, Zhang J, El Mongui A. Twelve-month comparative study of the impacts of IFNb-1a (Avonex), IFNb-1b (Betaseron) and glatiramer acetate (Copaxone) on the clinical, MRI and immunological responses in relapsing-remitting multiple sclerosis. Neurosciences (Official Journal of the Pan Arab Union of Neurological Sciences) 2003;8:93-4. [3193504]
    • (2003) Neurosciences (Official Journal of the Pan Arab Union of Neurological Sciences) , vol.8 , pp. 93-94
    • Salama, H.H.1    Abu-Hashim, E.M.2    El Bakry, M.A.3    Zhang, J.4    El Mongui, A.5
  • 43
    • 85000687759 scopus 로고    scopus 로고
    • Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments
    • [A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment]..., first received 19 November 2015). [4457779]
    • EUCTR2012-003735-32-GR Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments [A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment]. www.clinicaltrialsregister.eu/ctr-search/trial/2012-003735-32/GR. ., (first received 19 November 2015). [4457779]
  • 44
    • 85000678639 scopus 로고    scopus 로고
    • Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
    • [Phase IV, rater-blinded, randomized study, comparing 250 mg of betaseron with 20 mg of copaxone in patients with the relapsing-remitting(RR) or CIS forms of ms using 3 tesla (3T) magnetic resonance imaging (MRI) with triple-dose gadolinium]. (first received 13 September 2005). [3193506]
    • NCT00176592 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI [Phase IV, rater-blinded, randomized study, comparing 250 mg of betaseron with 20 mg of copaxone in patients with the relapsing-remitting(RR) or CIS forms of ms using 3 tesla (3T) magnetic resonance imaging (MRI) with triple-dose gadolinium]. ClinicalTrials.gov/show/NCT00176592 (first received 13 September 2005). [3193506]
  • 45
    • 85000874727 scopus 로고    scopus 로고
    • Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis
    • [A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)]. (first received 18 June 2012). [4457781]
    • NCT01623596 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis [A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)]. https://clinicaltrials.gov/ct2/show/study/NCT01623596 (first received 18 June 2012). [4457781]
  • 46
    • 47549090868 scopus 로고    scopus 로고
    • Temporal trends in the incidence of multiple sclerosis: a systematic review
    • [MEDLINE: 18606967]
    • Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71(2):129-35. [MEDLINE: 18606967]
    • (2008) Neurology , vol.71 , Issue.2 , pp. 129-135
    • Alonso, A.1    Hernan, M.A.2
  • 51
    • 0035091667 scopus 로고    scopus 로고
    • European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group
    • Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Annals of Neurology 2001;49(3):290-7.
    • (2001) Annals of Neurology , vol.49 , Issue.3 , pp. 290-297
    • Comi, G.1    Filippi, M.2    Wolinsky, J.S.3
  • 52
    • 54149084585 scopus 로고    scopus 로고
    • Multiple sclerosis
    • Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17.
    • (2008) Lancet , vol.372 , Issue.9648 , pp. 1502-1517
    • Compston, A.1    Coles, A.2
  • 54
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • [MEDLINE: 3802833]
    • DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833]
    • (1986) Controlled Clinical Trials , vol.7 , Issue.3 , pp. 177-188
    • DerSimonian, R.1    Laird, N.2
  • 55
    • 74249112995 scopus 로고    scopus 로고
    • Interferon beta mechanism of action in multiple sclerosis
    • Dhib-Jalbut S, Marks S. Interferon beta mechanism of action in multiple sclerosis. Neurology 2010;74(1 Suppl):17-24.
    • (2010) Neurology , vol.74 , Issue.1 , pp. 17-24
    • Dhib-Jalbut, S.1    Marks, S.2
  • 56
    • 84961894481 scopus 로고    scopus 로고
    • Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis
    • Dubey D, Cano CA, Stüve O. Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Current Opinion in Neurology 2016;29(3):278-85.
    • (2016) Current Opinion in Neurology , vol.29 , Issue.3 , pp. 278-285
    • Dubey, D.1    Cano, C.A.2    Stüve, O.3
  • 57
    • 85052341842 scopus 로고    scopus 로고
    • ® Product Approval Information - Application No 103471- July 1993
    • (accessed September 2016)
    • ® Product Approval Information - Application No 103471- July 1993. http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103471s0000_APPROV.pdf (accessed September 2016).
  • 58
    • 85052347625 scopus 로고    scopus 로고
    • ® Product Approval Information - Application N. 103628 - May 1996
    • (accessed September 2016)
    • ® Product Approval Information - Application N. 103628 - May 1996. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1996/ifnbbio051796l.pdf (accessed September 2016).
  • 59
    • 85052351070 scopus 로고    scopus 로고
    • ® Product Approval Information - NDA 020622/S-015 - March 2001
    • (accessed September 2016)
    • ® Product Approval Information - NDA 020622/S-015 - March 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020622_S015_COPAXONE_INJECTION_AP.pdf (accessed September 2016).
  • 60
    • 85052351512 scopus 로고    scopus 로고
    • ® Product Approval Information - Application No 103780 - March 2002
    • (accessed September 2016)
    • ® Product Approval Information - Application No 103780 - March 2002. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm094508.pdf (accessed September 2016).
  • 61
    • 85052340998 scopus 로고    scopus 로고
    • ® Product Approval Information - Application No.125290 - August 2009
    • (accessed September 2016)
    • ® Product Approval Information - Application No.125290 - August 2009. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/125290s0000ltr.pdf (accessed September 2016).
  • 62
    • 80052395734 scopus 로고    scopus 로고
    • Safety - What is a Serious Adverse Event?
    • (accessed September 2016)
    • U.S. Food, Drug Administration. Safety - What is a Serious Adverse Event?. http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm (accessed September 2016).
  • 63
    • 85052349698 scopus 로고    scopus 로고
    • ® Product Approval Information- BLA 125499/S-011- August 2014
    • (accessed September 2016)
    • ® Product Approval Information- BLA 125499/S-011- August 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125499s011lbl.pdf (accessed September 2016).
  • 64
    • 79954574768 scopus 로고    scopus 로고
    • Interferon -1b and glatiramer acetate effects on permanent black hole evolution
    • Filippi M, Rocca MA, Camesasca F, Cook S, O' Connor P, Arnason BG, et al. Interferon -1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76(14):1222-8.
    • (2011) Neurology , vol.76 , Issue.14 , pp. 1222-1228
    • Filippi, M.1    Rocca, M.A.2    Camesasca, F.3    Cook, S.4    O' Connor, P.5    Arnason, B.G.6
  • 67
    • 58149340114 scopus 로고    scopus 로고
    • Disease-modifying therapy in multiple sclerosis. Update and clinical implications
    • Goodin DS. Disease-modifying therapy in multiple sclerosis. Update and clinical implications. Neurology 2008;71 Suppl 3:8-13.
    • (2008) Neurology , vol.71 , pp. 8-13
    • Goodin, D.S.1
  • 68
    • 51649088205 scopus 로고    scopus 로고
    • Comparative studies of glatiramer acetate and interferon beta
    • Goodin D. Comparative studies of glatiramer acetate and interferon beta. International Multiple Sclerosis Journal 2008;15(2):39-41.
    • (2008) International Multiple Sclerosis Journal , vol.15 , Issue.2 , pp. 39-41
    • Goodin, D.1
  • 70
    • 3042651139 scopus 로고    scopus 로고
    • Grading quality of evidence and strength of recommendations
    • GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4.
    • (2004) BMJ , vol.328 , pp. 1490-1494
  • 71
    • 84856545931 scopus 로고    scopus 로고
    • GRADEpro
    • Version 3.2 for Windows. GRADE Working Group,
    • Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows. GRADE Working Group, 2008.
    • (2008)
    • Brozek, J.1    Oxman, A.2    Schünemann, H.3
  • 72
    • 84886950127 scopus 로고    scopus 로고
    • A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis
    • Hadjigeorgiou G, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, et al. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Journal of Clinical Pharmacy and Therapeutics 2013;38(6):433-9.
    • (2013) Journal of Clinical Pharmacy and Therapeutics , vol.38 , Issue.6 , pp. 433-439
    • Hadjigeorgiou, G.1    Doxani, C.2    Miligkos, M.3    Ziakas, P.4    Bakalos, G.5    Papadimitriou, D.6
  • 74
    • 85000356104 scopus 로고    scopus 로고
    • Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011
    • Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
    • Available from handbook.cochrane.org
    • Higgins, J.P.1    Green, S.e.2
  • 75
    • 84872299199 scopus 로고    scopus 로고
    • In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No
    • Hillert J. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No. Multiple Sclerosis (Houndmills, Basingstoke, England) 2012;19(1):26-8.
    • (2012) Multiple Sclerosis (Houndmills, Basingstoke, England) , vol.19 , Issue.1 , pp. 26-28
    • Hillert, J.1
  • 76
    • 84872329963 scopus 로고    scopus 로고
    • In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary
    • Hutchinson M. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary. Multiple Sclerosis (Houndmills, Basingstoke, England) 2012;19(1):29-30.
    • (2012) Multiple Sclerosis (Houndmills, Basingstoke, England) , vol.19 , Issue.1 , pp. 29-30
    • Hutchinson, M.1
  • 77
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    • The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43(4):655-61.
    • (1993) Neurology , vol.43 , Issue.4 , pp. 655-661
  • 78
    • 0008678962 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
    • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology 1996;39(3):285-94.
    • (1996) Annals of Neurology , vol.39 , Issue.3 , pp. 285-294
    • Jacobs, L.D.1    Cookfair, D.L.2    Rudick, R.A.3    Herndon, R.M.4    Richert, J.R.5    Salazar, A.M.6
  • 79
    • 84933521062 scopus 로고    scopus 로고
    • Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability
    • Jelinek GA, Weiland TJ, Hadgkiss EJ, Marck CH, Pereira N, Dania M, van der Meer DM. Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability. Neurological Research 2015;37(8):662-73.
    • (2015) Neurological Research , vol.37 , Issue.8 , pp. 662-673
    • Jelinek, G.A.1    Weiland, T.J.2    Hadgkiss, E.J.3    Marck, C.H.4    Pereira, N.5    Dania, M.6    van der Meer, D.M.7
  • 80
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group
    • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76.
    • (1995) Neurology , vol.45 , Issue.7 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3    Ford, C.C.4    Goldstein, J.5    Lisak, R.P.6
  • 81
    • 0021035886 scopus 로고
    • Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)
    • [MEDLINE: 84040263]
    • Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33(11):1444-52. [MEDLINE: 84040263]
    • (1983) Neurology , vol.33 , Issue.11 , pp. 1444-1452
    • Kurtzke, J.F.1
  • 83
    • 84880265360 scopus 로고    scopus 로고
    • Efficacy and safety of interferon beta-1b sc in older RRMS patients-a posthoc analysis of the BEYOND study
    • Lampl C, Nagl S, Arnason B, Comi G, O'Connor P, Cook S, et al. Efficacy and safety of interferon beta-1b sc in older RRMS patients-a posthoc analysis of the BEYOND study. Journal of Neurology 2013;260(7):1838-45.
    • (2013) Journal of Neurology , vol.260 , Issue.7 , pp. 1838-1845
    • Lampl, C.1    Nagl, S.2    Arnason, B.3    Comi, G.4    O'Connor, P.5    Cook, S.6
  • 84
    • 84857714278 scopus 로고    scopus 로고
    • The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics
    • Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Multiple Sclerosis and Related Disorders 2012;1(2):81-6.
    • (2012) Multiple Sclerosis and Related Disorders , vol.1 , Issue.2 , pp. 81-86
    • Lindsey, J.W.1    Scott, T.F.2    Lynch, S.G.3    Cofield, S.S.4    Nelson, F.5    Conwit, R.6
  • 85
    • 84873112669 scopus 로고    scopus 로고
    • The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - clinical outcomes
    • Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, Nelson F, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - clinical outcomes. Neurology 2012;78(1 Suppl 1):PL02.00.
    • (2012) Neurology , vol.78 , Issue.1
    • Lublin, F.1    Cofield, S.2    Cutter, G.3    Conwit, R.4    Narayana, P.5    Nelson, F.6
  • 86
    • 85000536714 scopus 로고    scopus 로고
    • EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting
    • Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting. Neurology 2013;80:1.
    • (2013) Neurology , vol.80 , pp. 1
    • Lublin, F.1    Cofield, S.2    Cutter, G.3    Salter, A.4    Wang, J.5    Conwit, R.6
  • 87
    • 84896715772 scopus 로고    scopus 로고
    • Relapse activity in the CombiRx trial: blinded, 7-year extension results
    • Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. Relapse activity in the CombiRx trial: blinded, 7-year extension results. Neurology 2013;80(1 Suppl1):1.
    • (2013) Neurology , vol.80 , Issue.1 , pp. 1
    • Lublin, F.1    Cofield, S.2    Cutter, G.3    Salter, A.4    Wang, J.5    Conwit, R.6
  • 88
    • 0034955141 scopus 로고    scopus 로고
    • Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
    • MEDLINE: 11456302]
    • McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology 2001;50(1):121-7. [MEDLINE: 11456302]
    • (2001) Annals of Neurology , vol.50 , Issue.1 , pp. 121-127
    • McDonald, W.I.1    Compston, A.2    Edan, G.3    Goodkin, D.4    Hartung, H.P.5    Lublin, F.D.6
  • 90
    • 69949098534 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata
    • O' Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2009;8:981.
    • (2009) Lancet Neurology , vol.8 , pp. 981
    • O' Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Gooding, D.6
  • 91
    • 85000741361 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata
    • O' Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2011; Vol. 10:115.
    • (2011) Lancet Neurology , vol.10 , pp. 115
    • O' Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Gooding, D.6
  • 92
    • 85000549116 scopus 로고    scopus 로고
    • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata
    • O' Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2012;11:27.
    • (2012) Lancet Neurology , vol.11 , pp. 27
    • O' Connor, P.1    Filippi, M.2    Arnason, B.3    Comi, G.4    Cook, S.5    Gooding, D.6
  • 93
    • 84873929621 scopus 로고    scopus 로고
    • Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years
    • Oleen-Burkey M, Cyhaniuk A, Swallow E. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. Journal of Medical Economics 2013;16(3):397-406.
    • (2013) Journal of Medical Economics , vol.16 , Issue.3 , pp. 397-406
    • Oleen-Burkey, M.1    Cyhaniuk, A.2    Swallow, E.3
  • 94
    • 79951508577 scopus 로고    scopus 로고
    • Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials
    • Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. Journal of the Neurological Sciences 2010;302(1-2):96-105.
    • (2010) Journal of the Neurological Sciences , vol.302 , Issue.1-2 , pp. 96-105
    • Oliver, B.J.1    Kohli, E.2    Kasper, L.H.3
  • 97
    • 28544436950 scopus 로고    scopus 로고
    • Diagnostic criteria for multiple sclerosis: 2005 revision to the "McDonald Criteria"
    • MEDLINE: 16283615]
    • Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revision to the "McDonald Criteria". Annals of Neurology 2005;58(6):840-6. [MEDLINE: 16283615]
    • (2005) Annals of Neurology , vol.58 , Issue.6 , pp. 840-846
    • Polman, C.H.1    Reingold, S.C.2    Edan, G.3    Filippi, M.4    Hartung, H.P.5    Kappos, L.6
  • 100
    • 0020686503 scopus 로고
    • New diagnostic criteria for multiple sclerosis:guidelines for research protocols
    • MEDLINE: 83202737]
    • Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis:guidelines for research protocols. Annals of Neurology 1983;13(3):227-31. [MEDLINE: 83202737]
    • (1983) Annals of Neurology , vol.13 , Issue.3 , pp. 227-231
    • Poser, C.M.1    Paty, D.W.2    Scheinberg, L.3    McDonald, W.I.4    Davis, F.A.5    Ebers, G.C.6
  • 101
    • 0345601517 scopus 로고    scopus 로고
    • Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
    • PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
    • (1998) Lancet , vol.352 , pp. 1498-1504
  • 102
    • 74249111385 scopus 로고    scopus 로고
    • The mechanism of action of glatiramer acetate treatment in multiple sclerosis
    • Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010;74 Suppl 1:25-30.
    • (2010) Neurology , vol.74 , pp. 25-30
    • Racke, M.K.1    Lovett-Racke, A.E.2    Karandikar, N.J.3
  • 103
    • 84986221380 scopus 로고    scopus 로고
    • Review Manager 5 (RevMan)
    • Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration,
    • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
    • (2014)
  • 105
    • 0036091948 scopus 로고    scopus 로고
    • A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models
    • MEDLINE: 12022938]
    • Richards R, Sampson F, Beard S, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technology Assessment 2002;6(18):1-73. [MEDLINE: 12022938]
    • (2002) Health Technology Assessment , vol.6 , Issue.18 , pp. 1-73
    • Richards, R.1    Sampson, F.2    Beard, S.3    Tappenden, P.4
  • 107
    • 71849109068 scopus 로고    scopus 로고
    • Do interferon beta-1b and glatiramer acetate grow brain?
    • Rudick RA, Fisher E. Do interferon beta-1b and glatiramer acetate grow brain?. Lancet Neurology 2009;8(12):1085-6.
    • (2009) Lancet Neurology , vol.8 , Issue.12 , pp. 1085-1086
    • Rudick, R.A.1    Fisher, E.2
  • 108
    • 77954891546 scopus 로고    scopus 로고
    • Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight year follow-up
    • Rudick RA, Lee LC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight year follow-up. Archives of Neurology 2010;67(11):1329-35.
    • (2010) Archives of Neurology , vol.67 , Issue.11 , pp. 1329-1335
    • Rudick, R.A.1    Lee, L.C.2    Cutter, G.R.3    Miller, D.M.4    Bourdette, D.5    Weinstock-Guttman, B.6
  • 109
    • 84890740559 scopus 로고    scopus 로고
    • Chapter 11: Presenting results and Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011
    • Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
    • www.cochrane-handbook.org
    • Schünemann, H.J.1    Oxman, A.D.2    Higgins, J.P.T.3    Vist, G.E.4    Glasziou, P.5    Guyatt, G.H.6
  • 111
    • 84890730197 scopus 로고    scopus 로고
    • Chapter 10: Addressing reporting biases
    • In: Higgins JPT, Green S (editors). Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011
    • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
    • Cochrane Handbook for Systematic Reviews of Intervention
    • Sterne, J.A.C.1    Egger, M.2    Moher, D.3
  • 112
    • 51449088420 scopus 로고    scopus 로고
    • REGARD: what can we learn from randomised, open-label, head-to-head studies?
    • Sørensen S. REGARD: what can we learn from randomised, open-label, head-to-head studies?. Lancet 2008; Vol. 7:864-6.
    • (2008) Lancet , vol.7 , pp. 864-866
    • Sørensen, S.1
  • 114
    • 0024504359 scopus 로고
    • The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability
    • Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46.
    • (1989) Brain , vol.112 , pp. 133-146
    • Weinshenker, B.G.1    Bass, B.2    Rice, G.P.3    Noseworthy, J.4    Carriere, W.5    Baskerville, J.6
  • 116
    • 85032039060 scopus 로고    scopus 로고
    • The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - MRI outcomes
    • Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - MRI outcomes. Neurology. 2012; Vol. 78, issue 1 Suppl 1:S11.002.
    • (2012) Neurology , vol.78 , Issue.1 , pp. S11002
    • Wolinsky, J.1    Narayana, P.2    Nelson, F.3    Datta, S.4    Cofield, S.5    Cutter, G.6
  • 118
    • 0021909115 scopus 로고
    • Beta-blockade during and after myocardial infarction: an overview of the randomised trials
    • Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Progress in Cardiovascular Diseases 1985;27(5):335-71.
    • (1985) Progress in Cardiovascular Diseases , vol.27 , Issue.5 , pp. 335-371
    • Yusuf, S.1    Peto, R.2    Lewis, J.3    Collins, R.4    Sleight, P.5
  • 119
    • 85041725660 scopus 로고    scopus 로고
    • A network meta-analysis assessing the rate of adverse events and drop outs of alternative treatments for relapsing forms of multiple sclerosis
    • Zagmutt F, Carroll C. A network meta-analysis assessing the rate of adverse events and drop outs of alternative treatments for relapsing forms of multiple sclerosis. Neurology. 2013; Vol. 80, issue 7 Suppl 1:1.
    • (2013) Neurology , vol.80 , Issue.7 , pp. 1
    • Zagmutt, F.1    Carroll, C.2
  • 120
    • 84929989445 scopus 로고    scopus 로고
    • Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study
    • Zhornitsky S, Greenfield J, Koch MW, Patten SB, Harris C, Wall W, et al. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. PLoS One 2015;10(4):e0123824.
    • (2015) PLoS One , vol.10 , Issue.4
    • Zhornitsky, S.1    Greenfield, J.2    Koch, M.W.3    Patten, S.B.4    Harris, C.5    Wall, W.6
  • 121
    • 47549113346 scopus 로고    scopus 로고
    • Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
    • Zivadinov R, Reder AT, Filippi M, Minagar A, Stüve O, Lassmann H, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71(2):136-44.
    • (2008) Neurology , vol.71 , Issue.2 , pp. 136-144
    • Zivadinov, R.1    Reder, A.T.2    Filippi, M.3    Minagar, A.4    Stüve, O.5    Lassmann, H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.